Related Experiment Videos
[Safety of lornoxicam in G-6-PDH deficiency]
G Perpignano1, E Cacace, C Matulli
1Cattedra di Reumatologia I, Università degli Studi di Cagliari, Italia.
Objective:
To assess the safety of lornoxicam in subjects with G-6-PDH deficiency.
Methods:
Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.
Results:
In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age +/- SD, 54.3 years +/- 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment.
Conclusions:
Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.
Insights
Lornoxicam is safe for patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This study found no red blood cell damage in G6PD-deficient patients treated with lornoxicam for rheumatic diseases.
Area of Science:
- Pharmacology
- Hematology
- Rheumatology
Background:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited red blood cell disorder.
- Non-steroidal anti-inflammatory drugs (NSAIDs) like lornoxicam can potentially trigger hemolysis in G6PD-deficient individuals.
Purpose of the Study:
- To evaluate the safety and tolerability of lornoxicam in patients diagnosed with G6PD deficiency.
- To assess the impact of lornoxicam on red blood cell (RBC) survival in this patient population.
Main Methods:
- An open-label, controlled, 2-week in vivo study was conducted.
- Eight male patients with the Mediterranean form of G6PD deficiency and rheumatic diseases participated.
- Lornoxicam was administered at a dosage of 8 mg twice daily.
Main Results:
- Lornoxicam treatment did not affect the red blood cell survival curve in the studied patients.
- The mean RBC half-life remained consistent before and after the two-week treatment period.
- No evidence of hemolysis or RBC damage was observed during the study.
Conclusions:
- Lornoxicam demonstrated a favorable safety profile in patients with G6PD deficiency.
- The drug did not induce any significant RBC damage or adverse hematological effects.
- Lornoxicam can be considered a safe treatment option for rheumatic diseases in individuals with G6PD deficiency.